Companies focused on psychedelic drug development are applying rigorous clinical trial design and methodology to validate what many cultures and societies have known to be true for hundreds, if not thousands, of years. As in the broader biotech field, many psychedelics researchers are looking to forward a more pragmatic approach to drug discovery and development, which may involve innovative…

Source

Previous articlePTSF67 – Psilocybin, Power, and Patents
Next articleNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD